Video Lectures
State-of-the-industry video lectures by leading urology experts
Latest Videos

ORLANDO, FL USA ( - Dr. Fred Saad presented a multi-institutional, exploratory analysis to evaluate the effect of prior endocrine therapy on clinical benefit of abiraterone (AA) in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer (mCRPC) in the randomized phase III study, COU-AA-302. A total of 1 088 patients who received continuous gonadotropin-releasing hormone [GnRH] agonists were randomized 1:1 to AA (1 g) + prednisone (P) (5 mg BID) or placebo + P. Radiographic progression-free survival (rPFS) and OS were “co-primary” end points of this trial. The rPFS was defined as time to first occurrence of bone scan, CT, or MRI progression, or death, whichever came first. They compared the treatment effect of AA on rPFS (investigator review at 55% of OS events) for subgroups above or below the median duration of prior endocrine therapy in 2 categories: prior GnRH agonists and androgen receptor (AR) inhibitors. Cox model was used to obtain the hazard ratio (HR) and associated 95% confidence interval (CI) with statistical inference by log rank statistic.

auaAccording to Dr. Saad, irrespective of median duration of prior GnRH agonist or AR inhibitor therapy, rPFS was significantly more favorable with AA + P than placebo + P. Moreover, increased median rPFS was evident in patients who had longer prior exposure to GnRH agonists or AR inhibitors, as compared to both AA + P and placebo + P treatment groups.

Abiraterone is a specific CYP17 inhibitor, and with prednisone, randomized clinical trials have shown that it can have significant improvement in rPFS in chemotherapy-naïve, asymptomatic or mildly symptomatic men who have progressive mCRPC. In this exploratory analysis, clinical benefit with AA + P vs placebo + P was demonstrated by significantly improved rPFS, regardless of whether men had exposure to prior endocrine therapy above or below the median duration of 37 and 16 months for GnRH agonists or AR inhibitors, respectively. Prior GnRH agonist and anti-androgen treatment duration should be further studied in order to fully assess their impact.

Click HERE to view the poster from this session

Presented by Fred Saad, MD, FRCSC at the American Urological Association (AUA) Annual Meeting- May 16 - 21, 2014 - Orlando, Florida USA

University of Montreal Hospital Centers, Montreal, Quebec Canada

Written by Reza Mehrazin, MD, medical writer for


Upcoming urology industry events
August 1-5, 2018 / Sheraton Philadelphia Society Hill Hotel
SUFU Research Foundation Resident Preceptorship 2018
August 3-4, 2018 / Hyatt Regency Washington on Capitol Hill
Best of ASCO 2018 - Washington, DC
August 10-11, 2018 / The Palmer House Hilton, Chicago, IL
Best of ASCO 2018 - Chicago, IL
August 28-31, 2018 / ICS 2018
International Continence Society 2018
Print publications focusing on urological cancer treatments through original commentary & articles
Everyday Urology Volume 2 Issue 4

Everyday Urology™ - Oncology Insights

From the Editor

PCAN cover

Prostate Cancer and Prostatic Diseases

From the Editor